A Phase 1/2 interventional study of CT7001 and Fulvestrant in Advanced Solid Malignancies, sponsored by Carrick Therapeutics Limited. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Carrick Therapeutics Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.
Module 1 comprises two sequential parts:
Part B: To refine the safety, tolerability, and PK and PD profiles of CT7001 monotherapy in participants with advanced solid malignancies from up to four tumour- specific cohorts, which may include, but is not limited to, triple-negative breast cancer, ovarian cancer, small-cell lung cancer and prostate cancer.
10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 124 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Carrick Therapeutics Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Core Inclusion Criteria:
Core Exclusion Criteria:
Impaired hepatic or renal function as demonstrated by any of the following laboratory values:
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
Additional Module 1A Inclusion Criteria:
Additional Module 1A Exclusion Criteria:
1. (INR) ≥1.5
Additional Module 1B Inclusion Criteria
Additional Module 1B-1 (TNBC Expansion) Inclusion Criteria:
Additional Module 1B-1 (TNBC Expansion) Exclusion Criteria:
Additional Module 2A Inclusion Criteria:
Additional Module 2A Exclusion Criteria:
Additional Module 4 Inclusion Criteria:
Additional Module 4 Exclusion Criteria:
1. Patients who were unable to fast for at least 10 hours
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Module 1 Part A Multiple ascending dose cohort: Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). Following completion of the dose escalation part of Module 1A, participants to receive safe, tolerable and MBAD of CT7001 for the paired biopsy expansion cohort. Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort: Participants with locally advanced or metastatic breast cancer will receive CT7001 (samuraciclib) as oral monotherapy at the minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D).
Drug: CT7001
Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
Drug: CT7001
Participants with castrate resistant prostate cancer will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
Drug: CT7001
Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) at the dose, frequency and schedule recommended from Module 1 part A and will receive Fulvestrant solution in pre-filled syringe for intramuscular (IM) injection
Drug: CT7001 · Drug: Fulvestrant
Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
Drug: CT7001
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Also known as: Samuraciclib
Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
Also known as: Faslodex
Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)
Treatment-emergent adverse events (TEAEs) are defined as those AEs which occur from Cycle 0 Day 1/Cycle 1 Day 1 of the study module to 28 days after the last dose of CT7001 in a module. Results reported below for Participants with one or more related TEAEs.
Time frame: Screening to end of study (28-35 calendar days after end of treatment). End of treatment at disease progression, unacceptable toxicity or withdrawal of consent. Average time on study 142.6 days (range 9 - 1135 days)
Maximum Plasma Concentration of CT7001 (Cmax)
Cmax is the maximum observed plasma concentration of CT7001 following oral dosing.
Time frame: After the first dose and during the dosing period (from the time of dose administration to 24 hours) for Module 1A cohorts. Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, 72, 120 and 168 hours post dose for Module 4 Cohorts.
Area Under the Curve (AUC)
Area under the plasma concentration-time curve representing the total drug exposure over time.
Time frame: After the first dose and during the dosing period (from the time of dose administration to 24 hours) for Module 1A. Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, 72, 120 and 168 hours post dose for Module 4 Cohorts.
Mean Trough Plasma Pharmacokinetic Concentrations for CT7001
Mean Trough Plasma Pharmacokinetic Concentrations is the lowest concentration of a drug in the bloodstream during a dosing interval. Timeframe: On study sampling: M1A - Day 1, 8, 15, 22, 29, 43, 50, every 21 days thereafter and EOT. M1B-1 and M1B-2: Day1, 8, 22, every 21 days thereafter and EOT. M2A: Day1, 15, 29, 57, every 56 days thereafter and EOT. M4: Day 1, 8, 15, 22, 29, 36, every 21 days thereafter and EOT.
Time frame: From enrolment (Day 1) through to disease progression, unacceptable toxicity or withdrawal of consent, whichever came first (EOT). Assessed up to 1135 days. On study pre-dose sampling for all modules (see outcome measure description).
Mean Trough Plasma Pharmacokinetic Concentrations for Fulvestrant (Module 2A)
Mean trough plasma PK concentrations refer to the lowest concentration of a drug in the bloodstream during a dosing interval.
Time frame: From enrolment through to disease progression, unacceptable toxicity or withdrawal of consent, whichever came first (EOT). Pre-dose sampling at Day 1, 15, 29, 57 and every 56 days thereafter and EOT. Assessed up to 848 days.
Anti-tumour Activity According to RECIST v1.1-Best Objective Response
Antitumour activity endpoints were analysed using the evaluable for Response population (any patient with at least one post baseline RECIST assessment). Best objective response is defined as the best response recorded from the start of study treatment to the end of treatment, including any assessments for confirmation after the end of treatment. Percentage of participants with each response calculated was based on the total number of participants with a baseline RECIST assessment. Timeframe: Scan frequency - Modules 1A and 4 (every 6 weeks); Modules 1B-1 and 2A (every 8 weeks first year, every 12 weeks thereafter); Module 1B-2 (every 8 weeks for the 6 months, every 12 weeks thereafter).
Time frame: From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1135 days (162 weeks). Frequency in outcome measure description.
Anti-tumour Activity According to RECIST v1.1-Progression Free Survival
Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Progression free survival is defined as the time from start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant had withdrawn from therapy or had received another anti-cancer therapy prior to progression. Participants who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
Time frame: From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first. Modules 1B-1 and 2A: every 8 weeks first year, every 12 weeks thereafter) assessed up to 848 days (121 weeks).
Anti-tumour Activity According to RECIST v1.1-Clinical Benefit Rate (CBR)
Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Clinical Benefit Rate (CBR) is defined as the percentage of subjects with a confirmed objective response of complete response or partial response, or stabilisation of disease for at least 24 weeks.
Time frame: From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first. Module 2A: every 8 weeks first year, every 12 weeks thereafter) assessed up to 848 days (121 weeks).
This study recruited participants at least 18 years of age with histological or cytological confirmation of an advanced malignancy, with an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 and an estimated life expectancy greater than 12 weeks.
| Milestone | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120 mg OD Fed-Fasted (Sequence 1) | Module 4 120 mg OD Fasted-Fed (Sequence 2) | Module 4 360 mg OD Fed-Fasted (Sequence 3) | Module 4 360 mg OD Fasted-Fast (Sequence 4) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 7 | 6 | 6 | 8 | 5 | 6 | 23 | 11 | 6 | 25 | 4 | 4 | 4 | 3 |
| Completed | 6 | 7 | 6 | 6 | 8 | 5 | 6 | 23 | 11 | 6 | 25 | 4 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events (TEAEs) are defined as those AEs which occur from Cycle 0 Day 1/Cycle 1 Day 1 of the study module to 28 days after the last dose of CT7001 in a module. Results reported below for Participants with one or more related TEAEs.
| Participants | Module 1 PartA-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2A 240 mg OD | Module 2A 360 mg OD | Module 4 120 mg OD Fed | Module 4 120mg OD Fasted | Module 4 360 mg OD Fed | Module 4 360mg OD Fasted | Module 4 240 mg OD Continuous Dosing | Module 4 360 mg OD Continuous Dosing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability) | 6 | 7 | 6 | 6 | 8 | 5 | 6 | 22 | 11 | 6 | 24 | 0 | 5 | 5 | 4 | 8 | 7 |
Cmax is the maximum observed plasma concentration of CT7001 following oral dosing.
| ng/mL | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 4 120 mg OD Fed | Module 4 120 mg OD Fasted | Module 4 360 mg OD Fed | Module 4 360 mg OD Fasted |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration of CT7001 (Cmax) | 89.15 ± 106.9 | 201.4 ± 22.25 | 172.8 ± NA | 270.2 ± 45.69 | 233.3 ± 28.75 | 19.21 ± 149.1 | 63.77 ± 108.8 | 138.8 ± 19.72 | 176.1 ± 63.91 |
Area under the plasma concentration-time curve representing the total drug exposure over time.
| h*ng/mL | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 4-120 mg OD Fed | Module 4 120 mg OD Fasted | Module 4 360 mg OD Fed | Module 4 360 mg OD Fasted |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve (AUC) | 802.9 ± 83.83 | 1926 ± 18.75 | 2506 ± NA | 2791 ± 27.63 | 1377 ± 15.21 | 785.3 ± 14.26 | 694.9 ± 55.93 | 2696 ± 41.38 | 2545 ± 66.10 |
Mean Trough Plasma Pharmacokinetic Concentrations is the lowest concentration of a drug in the bloodstream during a dosing interval. Timeframe: On study sampling: M1A - Day 1, 8, 15, 22, 29, 43, 50, every 21 days thereafter and EOT. M1B-1 and M1B-2: Day1, 8, 22, every 21 days thereafter and EOT. M2A: Day1, 15, 29, 57, every 56 days thereafter and EOT. M4: Day 1, 8, 15, 22, 29, 36, every 21 days thereafter and EOT.
| ng/mL | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4 240 mg OD (Continuous Dosing Phase) | Module 4 360 mg OD (Continuous Dosing Phase) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Trough Plasma Pharmacokinetic Concentrations for CT7001 | 16.12 ± 71.17 | 44.60 ± 32.05 | 60.60 ± NA | 63.40 ± 47.89 | 55.91 ± 78.90 | 39.22 ± 41.48 | 41.56 ± 47.94 | NA ± NA | 68.97 ± 69.2 | 47.87 ± 41.44 | 34.26 ± 138.3 |
Mean trough plasma PK concentrations refer to the lowest concentration of a drug in the bloodstream during a dosing interval.
| ng/mL | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) |
|---|---|---|
| Mean Trough Plasma Pharmacokinetic Concentrations for Fulvestrant (Module 2A) | 12.65 ± 13.88 | 12.47 ± 36.96 |
Antitumour activity endpoints were analysed using the evaluable for Response population (any patient with at least one post baseline RECIST assessment). Best objective response is defined as the best response recorded from the start of study treatment to the end of treatment, including any assessments for confirmation after the end of treatment. Percentage of participants with each response calculated was based on the total number of participants with a baseline RECIST assessment. Timeframe: Scan frequency - Modules 1A and 4 (every 6 weeks); Modules 1B-1 and 2A (every 8 weeks first year, every 12 weeks thereafter); Module 1B-2 (every 8 weeks for the 6 months, every 12 weeks thereafter).
| participants | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part ACT7001 240 mg OD +Fulvestrant (Cohort 1) | Module 2 Part ACT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120mg OD Fed | Module 4 120mg OD Fasted | Module 4 360mg OD Fed | Module 4 360mg OD Fasted | Module 4 240 mg OD Continuous Dosing | Module 4 360 mg OD Continuous Dosing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | 0 | 0 |
| Partial response | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | — | — | — | — | 0 | 0 |
| Stable disease | 2 | 3 | 0 | 4 | 4 | 2 | 3 | 11 | 5 | 3 | 10 | — | — | — | — | 5 | 4 |
| Progressive disease | 4 | 2 | 2 | 2 | 3 | 2 | 2 | 8 | 5 | 2 | 7 | — | — | — | — | 3 | 3 |
| Not evaluable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | — | — | — | — | 0 | 0 |
Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Progression free survival is defined as the time from start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant had withdrawn from therapy or had received another anti-cancer therapy prior to progression. Participants who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.
| days | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion. | Module 2 Part ACT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part ACT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4 120 mg OD Fed | Module 4 120mg OD Fasted | Module 4 360 mg OD Fed | Module 4 360mg OD Fasted | Module 4 240 mg OD Continuous Dosing | Module 4 360 mg OD Continuous Dosing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-tumour Activity According to RECIST v1.1-Progression Free Survival | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 72 (56 to 113) | NA (NA to NA) | 107 (51 to NA) | 114 (56 to 421) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Clinical Benefit Rate (CBR) is defined as the percentage of subjects with a confirmed objective response of complete response or partial response, or stabilisation of disease for at least 24 weeks.
| percentage of subjects | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part ACT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part ACT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4 120mg OD Fed | Module 4 120mg OD Fasted | Module 4 360mg OD Fed | Module 4 360mg OD Fasted | Module 4 240mg OD Continuous Dosing | Module 4 360mg OD Continous Dosing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-tumour Activity According to RECIST v1.1-Clinical Benefit Rate (CBR) | NA | NA | NA | NA | NA | NA | NA | NA | NA | 16.7 | 42.1 | NA | NA | NA | NA | NA | NA |
Collected over SAEs from consent, AEs from Day 1 to end of study (EOS). EOS (up to 35 days after EOT). EOT is date of first documented disease progression, unacceptable toxicity or withdrawal of consent, whichever came first. Assessed up to 1198 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Module 1 Part A-Cohort 1 120mg OD | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Module 1 Part A-Cohort 2 240mg OD | 1/12 (8.3%) | 4/12 (33.3%) | 12/12 (100%) |
| Module 1 Part A-Cohort 3 480mg OD | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Module 1 Part A-Cohort 4 360mg OD | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Module 1 Part A-Cohort 5 180mg BID | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | 2/23 (8.7%) | 9/23 (39.1%) | 23/23 (100%) |
| Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | 0/11 (0%) | 2/11 (18.2%) | 11/11 (100%) |
| Module 2 Part A CT7001 240mg OD + Fulvestrant (Cohort 1) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Module 2 Part A CT7001 360mg OD + Fulvestrant (Cohort 2) | 1/25 (4%) | 8/25 (32%) | 25/25 (100%) |
| Module 4 120mg OD Fed | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Module 4 120mg OD Fasted | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Module 4 360mg OD Fed | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Module 4 360mg OD Fasted | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Module 4 240mg OD Continuous Dosing | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Module 4 360mg OD Continous Dosing | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Event | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360mg OD + Fulvestrant (Cohort 2) | Module 4 120mg OD Fed | Module 4 120mg OD Fasted | Module 4 360mg OD Fed | Module 4 360mg OD Fasted | Module 4 240mg OD Continuous Dosing | Module 4 360mg OD Continous Dosing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/12 | 0/6 | 0/12 | 1/8 | 2/23 | 0/11 | 1/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| Atypical pneumoniaInfections and infestations | 0/6 | 0/12 | 0/6 | 0/12 | 0/8 | 0/23 | 0/11 | 1/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| BronchitisInfections and infestations | 1/6 | 0/12 | 0/6 | 0/12 | 0/8 | 0/23 | 0/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 1/12 | 0/6 | 0/12 | 0/8 | 0/23 | 0/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| Posterior reversible encephalopathy syndromeNervous system disorders | 0/6 | 0/12 | 0/6 | 0/12 | 0/8 | 0/23 | 0/11 | 1/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/12 | 0/6 | 0/12 | 0/8 | 1/23 | 0/11 | 0/6 | 1/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/6 | 0/12 | 0/6 | 0/12 | 0/8 | 0/23 | 0/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/6 | 0/12 | 1/6 | 0/12 | 0/8 | 0/23 | 0/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 0/7 |
| NauseaGastrointestinal disorders | 0/6 | 0/12 | 0/6 | 0/12 | 0/8 | 0/23 | 0/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 1/7 |
| Disease progressionGeneral disorders | 0/6 | 0/12 | 0/6 | 0/12 | 0/8 | 2/23 | 0/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 1/7 |
| Event | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240mg OD | Module 1 Part A-Cohort 3 480mg OD | Module 1 Part A-Cohort 4 360mg OD | Module 1 Part A-Cohort 5 180mg BID | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360mg OD + Fulvestrant (Cohort 2) | Module 4 120mg OD Fed | Module 4 120mg OD Fasted | Module 4 360mg OD Fed | Module 4 360mg OD Fasted | Module 4 240mg OD Continuous Dosing | Module 4 360mg OD Continous Dosing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/6 | 8/12 | 6/6 | 12/12 | 5/8 | 21/23 | 10/11 | 4/6 | 23/25 | 0/6 | 2/8 | 2/7 | 3/7 | 7/8 | 6/7 |
| NauseaGastrointestinal disorders | 5/6 | 9/12 | 3/6 | 11/12 | 6/8 | 22/23 | 8/11 | 6/6 | 19/25 | 0/6 | 3/8 | 2/7 | 0/7 | 7/8 | 4/7 |
| VomitingGastrointestinal disorders | 4/6 | 9/12 | 6/6 | 10/12 | 7/8 | 14/23 | 6/11 | 6/6 | 18/25 | 0/6 | 2/8 | 1/7 | 2/7 | 5/8 | 4/7 |
| Upper respiratory tract infectionInfections and infestations | 5/6 | 1/12 | 0/6 | 2/12 | 1/8 | 2/23 | 1/11 | 0/6 | 0/25 | 0/6 | 0/8 | 0/7 | 0/7 | 2/8 | 0/7 |
| FatigueGeneral disorders | 2/6 | 7/12 | 0/6 | 6/12 | 2/8 | 11/23 | 2/11 | 3/6 | 11/25 | 0/6 | 2/8 | 0/7 | 0/7 | 6/8 | 2/7 |
| HeadacheNervous system disorders | 0/6 | 0/12 | 2/6 | 1/12 | 1/8 | 0/23 | 0/11 | 4/6 | 4/25 | 0/6 | 1/8 | 0/7 | 0/7 | 1/8 | 0/7 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 2/12 | 1/6 | 3/12 | 1/8 | 3/23 | 6/11 | 2/6 | 11/25 | 0/6 | 1/8 | 1/7 | 0/7 | 3/8 | 2/7 |
| Abdominal painGastrointestinal disorders | 3/6 | 1/12 | 2/6 | 5/12 | 1/8 | 6/23 | 2/11 | 1/6 | 7/25 | 0/6 | 0/8 | 0/7 | 0/7 | 1/8 | 1/7 |
| ConstipationGastrointestinal disorders | 0/6 | 3/12 | 0/6 | 4/12 | 0/8 | 7/23 | 2/11 | 2/6 | 6/25 | 0/6 | 0/8 | 0/7 | 0/7 | 4/8 | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 1/6 | 5/12 | 1/6 | 2/12 | 1/8 | 1/23 | 3/11 | 1/6 | 3/25 | 0/6 | 0/8 | 0/7 | 0/7 | 0/8 | 1/7 |
| Age, Categorical(Participants) | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120 mg OD Fed-Fasted (Sequence 1) | Module 4 120 mg OD Fasted-Fed (Sequence 2) | Module 4 360 mg OD Fed-Fasted (Sequence 3) | Module 4 360 mg OD Fasted-Fed (Sequence 4) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 4 | 6 | 3 | 4 | 3 | 4 | 19 | 5 | 5 | 15 | 1 | 2 | 2 | 1 | 79 |
| >=65 years | 1 | 3 | 0 | 3 | 4 | 2 | 2 | 4 | 6 | 1 | 10 | 3 | 2 | 2 | 2 | 45 |
| Sex: Female, Male(Participants) | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120 mg OD Fed-Fasted (Sequence 1) | Module 4 120 mg OD Fasted-Fed (Sequence 2) | Module 4 360 mg OD Fed-Fasted (Sequence 3) | Module 4 360 mg OD Fasted-Fed (Sequence 4) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 6 | 3 | 6 | 5 | 6 | 23 | 0 | 6 | 25 | 0 | 2 | 2 | 1 | 91 |
| Male | 2 | 5 | 0 | 3 | 2 | 0 | 0 | 0 | 11 | 0 | 0 | 4 | 2 | 2 | 2 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120 mg OD Fed-Fasted (Sequence 1) | Module 4 120 mg OD Fasted-Fed (Sequence 2) | Module 4 360 mg OD Fed-Fasted (Sequence 3) | Module 4 360 mg OD Fasted-Fed (Sequence 4) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 4 | 5 | 6 | 6 | 8 | 5 | 5 | 18 | 6 | 5 | 21 | 4 | 4 | 2 | 3 | 102 |
| Unknown or Not Reported | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 5 | 5 | 1 | 2 | 0 | 0 | 2 | 0 | 20 |
| Race (NIH/OMB)(Participants) | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120 mg OD Fed-Fasted (Sequence 1) | Module 4 120 mg OD Fasted-Fed (Sequence 2) | Module 4 360 mg OD Fed-Fasted (Sequence 3) | Module 4 360 mg OD Fasted-Fed (Sequence 4) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| White | 4 | 5 | 6 | 6 | 7 | 5 | 6 | 19 | 8 | 6 | 20 | 4 | 4 | 4 | 3 | 107 |
| More than one race | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Module 1 Part A-Cohort 1 120mg OD | Module 1 Part A-Cohort 2 240 mg OD | Module 1 Part A-Cohort 3 480 mg OD | Module 1 Part A-Cohort 4 360 mg OD | Module 1 Part A-Cohort 5 180 mg BID | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mg | Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mg | Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion | Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion | Module 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1) | Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2) | Module 4-120 mg OD Fed-Fasted (Sequence 1) | Module 4 120 mg OD Fasted-Fed (Sequence 2) | Module 4 360 mg OD Fed-Fasted (Sequence 3) | Module 4 360 mg OD Fasted-Fed (Sequence 4) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 12 | 0 | 0 | 0 | 0 | 13 |
| United Kingdom | 6 | 7 | 6 | 6 | 8 | 5 | 6 | 23 | 11 | 5 | 13 | 4 | 4 | 4 | 3 | 111 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Dec 2022, 61 months.
Results were first posted in Jun 2026, 3 years 6 months after primary completion. A results delay was requested in Dec 2023.
Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 61 months is close to that.
Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Samuraciclib
Carrick Therapeutics Limited